Prelude Therapeutics Inc (PRLD): Capital Expenditures
$67.0K
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
-71.9%
3-year compound annual growth
-35.9%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $67.0K | -91.2% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $764.0K | -78.3% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $3.51M | +16.4% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $3.02M | +30.0% | 2024-02-15, From 2022-01-01 |
| 2021-12-31 | $2.32M | +274.1% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $621.0K | -20.4% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $780.0K | n/a | 2021-03-16, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $67.0K | -91.2% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $1.0K | -91.7% |
| Jaguar Health, Inc. (JAGX) | 2024-12-31 | $16.0K | n/a |
| Evommune, Inc. (EVMN) | 2025-12-31 | $235.0K | +167.0% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $3.37M | n/m |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $51.3K | n/a |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $919.0K | n/m |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $109.0K | +505.6% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $9.0K | -96.2% |
Compare PRLD, EMMA, JAGX, EVMN side by side · Screen every company in Pharmaceutical Preparations ↗